AI Maverick Intel issues 76.5M shares to HEAL Group under acquisition deal
What's the deal? AI Maverick Intel (AIMV), a New York-based company focused on healthcare, data, and AI, has issued 76.5 million common shares to HEAL Group Holdings as part of a right of first refusal (ROFR) agreement between the two parties. The shares represent an initial tranche of a total 100 million consideration shares tied to AIMV's planned acquisition of 100% of HEAL Access Canada Inc.
The ROFR agreement, effective since February 11, 2026, originally set the total consideration at 120 million shares but has since been adjusted down to 100 million. AIMV is also pursuing an uplisting to the OTCQB Venture Market as part of its broader capital markets strategy.
"The issuance of these shares reflects our continued execution on the strategic framework established with HEAL Group," said Wayne Cockburn, AIMV's chief executive officer.
Why now? HEAL Group Holdings is a privately held health-tech and wellness platform company backed by roughly $75M in family office capital invested over four years. It has assembled a portfolio of about 25 entities across North America and Europe, spanning healthcare services, digital health, AI, pharmaceutical distribution, and consumer wellness.
For AIMV, acquiring HEAL Access Canada — the AI division of HEAL's ecosystem — represents a move to gain a foothold in an integrated, data-driven healthcare platform at a time when AI applications in health are drawing significant investor interest.
What could go wrong? The deal is not yet finalised. The parties are still working toward a definitive agreement, and the transaction's completion depends on meeting minimum working capital requirements and other conditions. AIMV's forward-looking statements carry the standard caveat that actual results may differ materially from expectations.
The OTCQB uplisting is also conditional on meeting eligibility requirements — there's no guarantee it will happen.
The signal: This share-based acquisition underscores how micro-cap public companies are racing to bolt on AI-healthcare assets through equity deals rather than cash, hoping a compelling narrative will attract secondary-market interest. With HEAL Group backed by roughly $75 million in family office capital across some 25 portfolio entities, the ecosystem AIMV is buying into has meaningful scale — but the heavy share dilution (100 million consideration shares) places an outsized bet that the combined platform's value will grow fast enough to justify the cost to existing shareholders.
Read more: finanznachrichten.de
